1. Others
  2. Others

Azeliragon (Synonyms: TTP488)

Cat. No.: HY-50682 Purity: 98.79%
Handling Instructions

TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD).

For research use only. We do not sell to patients.

Azeliragon Chemical Structure

Azeliragon Chemical Structure

CAS No. : 603148-36-3

Size Price Stock Quantity
Free Sample (0.5-1 mg)   Apply now  
10 mM * 1 mL in DMSO USD 169 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
5 mg USD 144 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
10 mg USD 228 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
50 mg USD 660 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
100 mg USD 1080 In-stock
Stock in Sweden
Estimated Time of Arrival: December 31
200 mg USD 1800 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
500 mg USD 2520 In-stock
Stock in the United States
Estimated Time of Arrival: December 31
1 g   Get quote  
5 g   Get quote  

* Please select Quantity before adding items.

  • Biological Activity

  • Protocol

  • Technical Information

  • Purity & Documentation

  • References

Description

TTP488 is an antagonist at the Receptor for Advanced Glycation End products, is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer's disease (AD). Target: RAGE in vitro: TTP488 is an orally active, centrally acting antagonist of RAGE-RAGE ligand interaction. Chronic oral dosing of TTP488 in AD transgenic mice led to a reduction of amyloid load in the brain, improves performance on behavioral testing and normalization of electrophysiological recordings from hippocampal slices.[1] in vivo: The small molecule RAGE antagonist, TTP488, is developed by Trans-Tech Pharma. The TTP488 or control peptide is administered i.p. daily at a dose of 100 mcg/d.[3] Successful use of the RAGE inhibitor TTP488 in Phase II testing has led to a Phase III clinical trial for AD patients.[2]

Clinical Trial
References
Preparing Stock Solutions
Concentration Volume Mass 1 mg 5 mg 10 mg
1 mM 1.8793 mL 9.3964 mL 18.7928 mL
5 mM 0.3759 mL 1.8793 mL 3.7586 mL
10 mM 0.1879 mL 0.9396 mL 1.8793 mL
Please refer to the solubility information to select the appropriate solvent.
References
Molecular Weight

532.12

Formula

C₃₂H₃₈ClN₃O₂

CAS No.

603148-36-3

SMILES

ClC1=CC=C(C=C1)OC2=CC=C(C=C2)N3C(CCCC)=NC(C(C=C4)=CC=C4OCCCN(CC)CC)=C3

Storage
Powder -20°C 3 years
  4°C 2 years
In solvent -80°C 6 months
  -20°C 1 month
Shipping

Room temperature in continental US; may vary elsewhere

Solvent & Solubility

10 mM in DMSO

* "<1 mg/mL" means slightly soluble or insoluble. "≥" means soluble, but saturation unknown.

Inquiry Online

Your information is safe with us. * Required Fields.

Product name

 

Salutation

Applicant name *

 

Email address *

Phone number *

 

Organization name *

Country or Region *

 

Requested quantity *

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Azeliragon
Cat. No.:
HY-50682
Quantity: